Stay updated with breaking news from Developmental Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Another departure from thew mundane.....Trump yelled something....Biden walked slowly....McConnell forget something.....and Florida took a big hit. But I will not be reporting on any of that rather I will give you the news that time will forget. I start with the Yuk Factor..... The call went out to Dr. Sanjaya Senanayake, an infectious diseases physician…
2 posts published by lobotero on September 2, 2023
Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer. The combination therapy led to durable tumor elimination and significantly improved survival outcomes in preclinical models, leading to the launch of a Phase I clinical trial.